EHA 2019 featured several eagerly awaited presentations on Hodgkin lymphoma (HL). This included 3-year follow-up data of the ECHELON-1 trial in patients with high-risk features and longer follow-up data of CheckMate 2015 evaluating nivolumab plus doxorubicin, vinblastine, and dacarbazine in newly diagnosed advanced HL. In a third interesting HL abstract it was shown that foregoing radiotherapy in PET-negative patients with early-stage HL increases the risk of disease progression. In non-Hodgkin lymphoma (NHL), data were presented indicating that there is no benefit of rituximab maintenance beyond two years in patients with relapsed or refractory indolent NHL. In addition to this, interesting data were presented on the use of an obinutuzumab + DHAP combination in patients with untreated mantle cell lymphoma, with polatuzumab vedotin + obinutuzumab + lenalidomide in relapsed/refractory follicular lymphoma (FL) and with the anti-CD47 antibody Hu5F9-G4 in patients with refractory lymphoma.

(BELG J HEMATOL 2019;10(5):208–13)